You are here: Home » Reuters » News
Business Standard

U.S. FDA approves expanded use of AstraZeneca cancer drug


By Toni Clarke

(Reuters) - The said on Friday it has approved expanded use of Plc's drug to include patients with metastatic breast whose is associated with a mutation of the BRCA gene.

The drug belongs to a class of drug known as that has already been used to treat advanced BRCA-mutated ovarian cancer, the said.

This is the first time a PARP inhibitor has been approved to treat breast and the first time any drug has been approved to treat certain patients with metastatic breast associated with the same genetic mutation.

"This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of a cancer, often across types," said Dr. Richard Pazdur, of the FDA's oncology products division. Between 5-10 percent of patients with breast have a

Patients are selected for treatment based on a diagnostic test made by known as BRACAnalysis CDx. In 2014 Myriad won approval for the test to help identify patients with advanced ovarian considered eligible for treatment with the drug after others have failed.

In July and announced a global strategic oncology collaboration to jointly co-develop and co-commercialize Lynparza, an oral treatment known also as olaparib, for multiple type, both as a monotherapy and in combination with other potential drugs.

(Reporting by in Washington; Editing by and Susan Thomas)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, January 12 2018. 22:56 IST